Epigenetics in acute kidney injury

Different Biomarkers of Acute kidney Injury in Cancer Patients

Acute Kidney Injury (AKI) occurs if the kidneys suddenly lose their ability to remove waste products. When the kidneys lose their ability to filter, dangerous levels of waste products can accumulate, which can upset the chemical composition of the blood and urine. Chemotherapy is one of the methods used to treat or temporarily reduce cancer by using certain medications. The main task of this tr...

Renal kallikrein excretion and epigenetics in human acute kidney injury: Expression, mechanisms and consequences

BACKGROUND Renal kallikrein (KLK1) synthesis and urinary excretion are reportedly diminished during AKI (acute kidney injury) in animal models, and provision of kallikrein abrogates renal injury in this setting, but data in human AKI is limited. Therefore we first examined KLK1 renal excretion in human AKI, and then probed potential endocrine and epigenetic mechanisms for its alterations. MET...

NGAL, the New Marker for Acute Kidney Injury

Kidney-Heart Interactions in Acute Kidney Injury.

Acute kidney injury (AKI) is a common complication in critically ill patients treated in intensive care units. Renal replacement therapy (RRT)-requiring AKI occurs in approximately 5-10% patients in intensive care unit and their mortality rate is unacceptably high (50-60%), despite sufficient control of uremia using remarkably advanced modern RRT techniques. This suggests that there are unrecog...

Kidney-liver dialogue in acute kidney injury.

HEMOPEXIN IS A MULTIFUNCTIONAL serum glycoprotein that plays important roles in iron homeostasis, antioxidant protection, anti-inflammatory effects, and signal transduction pathways (6, 8). The liver is the main source of the hemopexin synthesis (7), but expression in other tissues including the retina, peripheral nerves, and neurons of the central nervous system has also been reported. Hemopex...